David de Graaf, Ph.D., President and CEO of Syntimmune |  August 2017
“‘The Development of Therapeutic Monoclonal Antibody Products’ is essential reading for biotech executives from the C-suite to senior operations personnel. It gives a clear, concise, and authoritative overview of the many CMC challenges that must be addressed to produce an antibody treatment that will meet regulatory muster and advance through clinical trials to ultimately help patients. Our regulatory and production team refers often to this book.” 

Anthony J. Sinskey, Sc.D., professor of microbiology and engineering systems at the Massachusetts Institute of Technology | August 2017
“BPTC is to be applauded for this new, expanded edition of ‘The Development of Therapeutic Monoclonal Antibody Products.’ In addition to providing companies with useful information that will enable them to speed their drug candidates through the many chemistry and manufacturing issues that will arise on the road to commercialization, the book will be an invaluable reference and teaching tool for those new to the field of monoclonal antibody development.”